Why Is PRAXIS PRECISION MED (PRAX) Stock Up Today?

PRAXIS PRECISION MED (PRAX) surged 14.72% to $366.01 in a volatile session driven by the release of second quarter 2026 financial results and a series of analyst upgrades and research developments. The stock opened with a 2.7% gap up and reached an intraday high of $372.00 before settling near the session close. The move followed a regulatory filing and multiple analyst reports highlighting the company's progress in drug development and financial performance.

What Happened

Praxis Precision Medicines reported Q2 2026 earnings per share of -$2.87, which beat the estimated -$3.65 loss. The company filed a Form 8-K disclosing its results of operations and financial condition, including a corporate update and regulatory disclosures. The report outlined a 365% year-to-date revenue increase, despite ongoing losses. In addition, Praxis announced a research collaboration with Remagine Labs to develop a transdermal patch for ulixacaltamide and received an FDA extension for the PDUFA date of relutrigine to December 27, 2026. Analyst coverage also intensified, with BTIG reiterating a Buy rating and a $810 price target, and Goldman Sachs initiating coverage with a Buy rating and a $447 price target.

What The Data Shows

The stock opened at $328.00 and traded as high as $372.00, with a volume of 0.1 million shares, or 0.3 times the 3-month average. Over the past eight sessions, the stock had risen 1.1% from $315.80 to $319.23. Insider transactions show one sale totaling $3.6 million in the last 90 days, with no insider purchases. The stock is currently trading near its 52-week high of $366.52 and has a market cap of $8.6 billion.

What To Watch

The company is scheduled to report further developments in the coming weeks, including potential updates on the relutrigine PDUFA timeline and ongoing research collaborations. Investors should monitor the breadth of analyst coverage and any new regulatory or financial disclosures.